NarcoBond: Opioid Targeted Biomimetic Nanosponges for Treatment of Opioid Overdose
NarcoBond:阿片类药物靶向仿生纳米海绵用于治疗阿片类药物过量
基本信息
- 批准号:9912595
- 负责人:
- 金额:$ 25.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-30 至 2023-09-29
- 项目状态:已结题
- 来源:
- 关键词:ARNT geneAcuteAddressAffinityBindingBiodistributionBiological AssayBiomimeticsBloodBlood CirculationBrainCaliberCell membraneCellsCellular AssayCholesterolCholineClinicalCodeineComplementDerivation procedureDevelopmentErythrocytesFatty acid glycerol estersFentanylHalf-LifeHostageHumanHydrocodoneIn VitroIntravenousLegal patentLifeLipid BilayersLiquid substanceLiverLymphMembraneMembrane ProteinsMethadoneMorphineMusNaloxoneNanosphereNeuronsNociceptionNociceptorsOpioidOpioid AntagonistOpioid ReceptorOpioid Receptor BindingOverdoseOxycodonePatientsPersonsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePhospholipidsProtocols documentationRecording of previous eventsRecurrenceResistanceRiskSavingsSerumSolidSubstance Withdrawal SyndromeSurfaceTerrorismTimeTissuesTranslatingUrineVaccinationVentilatory DepressionWeaningbasechemical threatclinical applicationcost effectivedrug of abusein vivoinduced pluripotent stem cellinnovationmedical countermeasuremu opioid receptorsnovelnovel strategiesoff-patentopioid epidemicopioid injectionopioid misuseopioid overdoseopioid useperipheral bloodscreeningtool
项目摘要
Abstract
We propose to develop a broad acute/sub-acute opioid drug detoxifying treatment for
opioid overdose that can complement & compensate for the deficiencies in nalaxone,
using opioid-targeted biomimetic “nanosponges” that absorb overdosed opioids in the
body. (Note: if this proof-of-concept is successful here, the approach may be tailored to other
drugs-of-abuse.) Called “NarcoBondTM” these 100 nm diameter nanospheres are assembled
from a mixture of cholesterol & synthetic choline-based phospholipids that mimic the lipid bilayer
cell membranes. Its multifunctional surface displays an optimized milieu of human membrane
proteins isolated from: a) erythrocytes to increase half-life in peripheral blood & circulation, b)
neurons to increase binding affinity for opioid receptor, & c) purified Mu opioid receptors to bind
opioids in circulation. The NarcoBond's repertoire of native opioid receptors broadly binds &
captures opioids from microenvironmental niches of cells in tissues & will result in an
antagonistic pharmacological effect by rapidly reducing the concentration of the overdosed
opioid.
Significance. Every 15 min. in the US, a person dies after overdosing on opioids.1 Naloxone, an
opioid receptor antagonist, is, to date, the only life-saving treatment for opioid overdose based
on its ability to reverse respiratory depression acutely.3 Yet the pharmacodynamic actions of
naloxone last for a briefer period than all but the most short acting opioids;3-9 although the
elimination half life of naloxone is similar to that of morphine (60–90')9 it is redistributed away
from the brain more rapidly.3 Consequently, the patients may become renarcotised after
naloxone treatment due to the continued presence of opioids in peripheral blood. In full
development, NarcoBond offers a more broad alternative for cost effective & longer lasting
means to cleanse the peripheral blood of opioids, reducing the risk of renarcotisation, &
assisting in the life-saving reversal of overdose-induced respiratory depression. While
prompting acute withdrawal syndrome (AWS) is always a risk in rapid opioid receptor blockade,
without renarcotisation's acute risk of recurrent respiratory depression, clinicians will
have more time to intervene with gradual weaning protocols to avoid AWS. In addition,
NarcoBond's broad capability to mitigate against all opioids including highly potent synthetic
acrylfentanyl (i.e., “naloxone resistant” chemical threat agents), addresses unmet need(s) for
medical countermeasures in terrorism & hostage scenarios.8,11
抽象的
我们建议开发一种广泛的急性/亚急性阿片类药物解毒治疗方法
阿片类药物过量可以补充和补偿纳络酮的不足,
使用以阿片类药物为目标的仿生“纳米海绵”,吸收过量的阿片类药物
身体。 (注意:如果这个概念验证在这里成功,该方法可能会针对其他
滥用药物。)这些直径为 100 nm 的纳米球被称为“NarcoBondTM”
来自模拟脂质双层的胆固醇和合成胆碱磷脂的混合物
细胞膜。其多功能表面显示出优化的人体膜环境
从以下来源分离出的蛋白质:a) 红细胞,可延长外周血液和循环中的半衰期,b)
神经元增加对阿片受体的结合亲和力,&c) 纯化的 Mu 阿片受体结合
流通中的阿片类药物。 NarcoBond 的天然阿片受体库广泛结合和
从组织细胞的微环境中捕获阿片类药物,并将导致
通过迅速降低过量药物的浓度而产生拮抗药理作用
阿片类药物。
意义。每 15 分钟一班在美国,有人因过量服用阿片类药物而死亡。1 纳洛酮,一种
阿片受体拮抗剂,是迄今为止唯一一种针对阿片类药物过量的救生治疗方法
其急性逆转呼吸抑制的能力。3 然而,其药效作用
纳洛酮的持续时间比除最短效阿片类药物外的所有药物都要短;3-9
纳洛酮的消除半衰期与吗啡相似 (60–90')9,它被重新分配
更快地从大脑中消失。3因此,患者可能会在术后再次麻醉。
由于外周血中持续存在阿片类药物,因此需要进行纳洛酮治疗。全文
开发,NarcoBond 提供了更广泛的替代方案,具有成本效益且更持久
净化外周血液中的阿片类药物,降低再次麻醉的风险,以及
协助挽救生命,逆转药物过量引起的呼吸抑制。尽管
提示急性戒断综合征(AWS)始终是快速阿片受体阻断的一个风险,
如果没有重新麻醉的复发性呼吸抑制的严重风险,临床医生将
有更多时间通过逐步断奶方案进行干预以避免 AWS。此外,
NarcoBond 具有广泛的能力,可以缓解所有阿片类药物,包括高效合成阿片类药物
丙烯酰芬太尼(即“纳洛酮抗性”化学威胁剂),解决了未满足的需求
恐怖主义和人质劫持情况下的医疗对策。8,11
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babak Esmaeli-Azad其他文献
Babak Esmaeli-Azad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babak Esmaeli-Azad', 18)}}的其他基金
NarcoBond: Opioid Targeted Biomimetic Nanosponges for Treatment of Opioid Overdose
NarcoBond:阿片类药物靶向仿生纳米海绵用于治疗阿片类药物过量
- 批准号:
10179237 - 财政年份:2019
- 资助金额:
$ 25.4万 - 项目类别:
Direct Conversion of Human Fibroblasts into Neuronal Cells by Small Molecules (hCiN)
通过小分子 (hCiN) 将人成纤维细胞直接转化为神经元细胞
- 批准号:
9254639 - 财政年份:2017
- 资助金额:
$ 25.4万 - 项目类别:
Human Chemically induced Pluripotent Stem Cells (CiPSC) generated Cardiomyocytes
人类化学诱导多能干细胞 (CiPSC) 产生的心肌细胞
- 批准号:
8059798 - 财政年份:2011
- 资助金额:
$ 25.4万 - 项目类别:
Chemically Induced Pluripotent Stem (CiPS) Cells Alzheimer's Patient Specific Cel
化学诱导多能干 (CiPS) 细胞 阿尔茨海默病患者特异性细胞
- 批准号:
7911334 - 财政年份:2010
- 资助金额:
$ 25.4万 - 项目类别:
HUMAN PROTEIN DIFFERENTIAL DISPLAY ASSAY ICAT-ULC-MS/MS
人类蛋白质差异显示测定 ICAT-ULC-MS/MS
- 批准号:
6311048 - 财政年份:2001
- 资助金额:
$ 25.4万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 25.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 25.4万 - 项目类别:
Operating Grants